User:Peyton Jenkins/Sandbox 1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 2: Line 2:
<StructureSection load='2WTK' size='340' side='right' caption='Heterotrimeric Complex of STK11, MO25, STRADα' scene=''>
<StructureSection load='2WTK' size='340' side='right' caption='Heterotrimeric Complex of STK11, MO25, STRADα' scene=''>
== Relevance and Disease ==
== Relevance and Disease ==
-
Lung cancer is the leading cause of cancer related death worldwide. In the United States alone, over 120,000 deaths were caused by lung cancer in 2024<ref>https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf</ref>. Non small cell lung cancer make up approximately 84% of all lung cancer cases, and of these lung adenocarcinoma accounts for about 65%<ref>10.1001/jamaoncol.2021.4932</ref>. In lung adenocarcinoma, ''STK11'' is the third most commonly mutated gene, behind only ''KRAS'' and ''p53''<ref>10.1091/mbc.E15-08-0569.</ref>. ''STK11'' driven lung cancers are associated with a more aggressive phenotype, with increased metastasis, lower overall survival, and higher resistance to current therapies, such as [https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors immune checkpoint inhibitors]<ref>Wohlhieter, C. A., Richards, A. L., Uddin, F., Hulton, C. H., Quintanal-Villalonga, A., Martin, A., de Stanchina, E., Bhanot, U., Asher, M., Shah, N. S., Hayatt, O., Buonocore, D. J., Rekhtman, N., Shen, R., Arbour, K. C., Donoghue, M., Poirier, J. T., Sen, T., and Rudin, C. M. (2020) Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer, Cell Rep 33, 108444.</ref><ref>Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., Ali, S. M., Elvin, J. A., Singal, G., Ross, J. S., Fabrizio, D., Szabo, P. M., Chang, H., Sasson, A., Srinivasan, S., Kirov, S., Szustakowski, J., Vitazka, P., Edwards, R., Bufill, J. A., Sharma, N., Ou, S. I., Peled, N., Spigel, D. R., Rizvi, H., Aguilar, E. J., Carter, B. W., Erasmus, J., Halpenny, D. F., Plodkowski, A. J., Long, N. M., Nishino, M., Denning, W. L., Galan-Cobo, A., Hamdi, H., Hirz, T., Tong, P., Wang, J., Rodriguez-Canales, J., Villalobos, P. A., Parra, E. R., Kalhor, N., Sholl, L. M., Sauter, J. L., Jungbluth, A. A., Mino-Kenudson, M., Azimi, R., Elamin, Y. Y., Zhang, J., Leonardi, G. C., Jiang, F., Wong, K. K., Lee, J. J., Papadimitrakopoulou, V. A., Wistuba, II, Miller, V. A., Frampton, G. M., Wolchok, J. D., Shaw, A. T., Janne, P. A., Stephens, P. J., Rudin, C. M., Geese, W. J., Albacker, L. A., and Heymach, J. V. (2018) STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma, Cancer Discov 8, 822-835.</ref>.
+
Lung cancer is the leading cause of cancer related death worldwide. In the United States alone, over 120,000 deaths were caused by lung cancer in 2024<ref>https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf</ref>. Non small cell lung cancer makes up approximately 84% of all lung cancer cases, and of these, lung adenocarcinoma accounts for about 65%<ref>10.1001/jamaoncol.2021.4932</ref>. In lung adenocarcinoma, the tumor suppressor ''STK11'' is the third most commonly mutated gene, behind only ''KRAS'' and ''p53''<ref>10.1091/mbc.E15-08-0569.</ref>. ''STK11'' driven lung cancers are associated with a more aggressive phenotype; with increased metastasis, lower overall survival, and higher resistance to current therapies, such as [https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors immune checkpoint inhibitors]<ref>Wohlhieter, C. A., Richards, A. L., Uddin, F., Hulton, C. H., Quintanal-Villalonga, A., Martin, A., de Stanchina, E., Bhanot, U., Asher, M., Shah, N. S., Hayatt, O., Buonocore, D. J., Rekhtman, N., Shen, R., Arbour, K. C., Donoghue, M., Poirier, J. T., Sen, T., and Rudin, C. M. (2020) Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer, Cell Rep 33, 108444.</ref><ref>Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., Ali, S. M., Elvin, J. A., Singal, G., Ross, J. S., Fabrizio, D., Szabo, P. M., Chang, H., Sasson, A., Srinivasan, S., Kirov, S., Szustakowski, J., Vitazka, P., Edwards, R., Bufill, J. A., Sharma, N., Ou, S. I., Peled, N., Spigel, D. R., Rizvi, H., Aguilar, E. J., Carter, B. W., Erasmus, J., Halpenny, D. F., Plodkowski, A. J., Long, N. M., Nishino, M., Denning, W. L., Galan-Cobo, A., Hamdi, H., Hirz, T., Tong, P., Wang, J., Rodriguez-Canales, J., Villalobos, P. A., Parra, E. R., Kalhor, N., Sholl, L. M., Sauter, J. L., Jungbluth, A. A., Mino-Kenudson, M., Azimi, R., Elamin, Y. Y., Zhang, J., Leonardi, G. C., Jiang, F., Wong, K. K., Lee, J. J., Papadimitrakopoulou, V. A., Wistuba, II, Miller, V. A., Frampton, G. M., Wolchok, J. D., Shaw, A. T., Janne, P. A., Stephens, P. J., Rudin, C. M., Geese, W. J., Albacker, L. A., and Heymach, J. V. (2018) STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma, Cancer Discov 8, 822-835.</ref>.
-
Germline loss of function mutations in ''STK11'' are associated with [https://my.clevelandclinic.org/health/diseases/17362-peutz-jeghers-syndrome-pjs Peutz-Jeghers Syndrome]. A precancerous condition characterized by the formation of polyps in the small intestine, and a predisposition to all cancers<ref>McGarrity TJ, Amos CI, Baker MJ. Peutz-Jeghers Syndrome. 2001 Feb 23 [updated 2021 Sep 2]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301443.</ref>.
+
Germline loss of function mutations in ''STK11'' are associated with [https://my.clevelandclinic.org/health/diseases/17362-peutz-jeghers-syndrome-pjs Peutz-Jeghers Syndrome]. A precancerous condition characterized by the formation of benign polyps in the small intestine, and a predisposition to all cancers<ref>McGarrity TJ, Amos CI, Baker MJ. Peutz-Jeghers Syndrome. 2001 Feb 23 [updated 2021 Sep 2]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301443.</ref>.
-
Serine/Threonine Kinase 11 ([[STK11]]) is a master kinase, signalling upstream of the AMP-Activated Protein Kinase ([[AMPK]]) family, [[p53]], and Focal Adhesion Kinase ([[FAK]]), to regulate processes like anoikis, adhesion, growth, metabolism, and survival<ref>10.1038/sj.emboj.7600110</ref><sup>, </sup><ref>10.1074/jbc.M112.444620</ref>. [[STK11]] exists in a <scene name='10/1078094/2wtk_labeled_complex/1'>heterotrimeric complex</scene> with the pseudokinase STE Related Adaptor Alpha (STRADα), and the scaffolding protein Mouse Protein 25 (MO25). Unlike other kinases that are activated by phosphorylation within the activation loop, STK11 is activated by the formation of this complex and thus it is essential for both proper kinase activity and proper localization. <ref>10.1038/sj.emboj.7600110</ref><sup>, </sup> <ref>10.1093/emboj/cdg490</ref>
+
Serine/Threonine Kinase 11 ([[STK11]]) is a master kinase, signalling upstream of the AMP-Activated Protein Kinase ([[AMPK]]) family, [[p53]], and Focal Adhesion Kinase ([[FAK]]), to regulate processes like anoikis, adhesion, growth, metabolism, and survival<ref>10.1038/sj.emboj.7600110</ref><sup>, </sup><ref>10.1074/jbc.M112.444620</ref>. [[STK11]] exists in a <scene name='10/1078094/2wtk_labeled_complex/1'>heterotrimeric complex</scene> with the pseudokinase STE Related Adaptor Alpha (STRADα), and the scaffolding protein Mouse Protein 25 (MO25). Unlike other kinases that are activated by phosphorylation within the activation loop, STK11 is activated by the formation of this complex and thus it is essential for both proper kinase activity and proper localization. <ref>10.1038/sj.emboj.7600110</ref><sup>, </sup> <ref>10.1093/emboj/cdg490</ref>
== Structural Highlights ==
== Structural Highlights ==
=== STK11 ===
=== STK11 ===
-
[[STK11]] can be broken down into 3 domains. An N-terminal domain (aa 1-42), kinase domain (aa 43-347), and a C-terminal domain (aa 348-433). The <scene name='10/1078094/Active_site/1'>activation loop</scene> of [[STK11]] is located from residues ~202-212. Within the activation loop is F204, which interacts with a hydrophobic pocket on MO25, which is necessary to stabilize the active conformation. Within the αC helix is residue D98 which forms a <scene name='10/1078094/78and98/2'>salt bridge</scene> with K78, further stabilizing the active site and aids in ATP binding. Mg<sup>2+</sup> helps aid ATP binding, however in this structure there is a point mutation (<scene name='10/1078094/D194a/1'>D194A</scene>) to make STK11 catalytically inactive. Another loop, the <scene name='10/1078094/B2b3_loop/2'>β2-β3 loop</scene> is essential for binding of STRADα on the N-terminal lobe of STK11. β7-β8 sheets of STK11 also interact with STRADα. In the β2-β3 loop R74 hydrogen bonds with Q251 of STRADα<ref>(1.) Zeqiraj, E., Filippi, B. M., Deak, M., Alessi, D. R., and van Aalten, D. M. (2009) Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation, Science 326, 1707-1711.
+
[[STK11]] can be broken down into 3 domains. An N-terminal domain (aa 1-42), kinase domain (aa 43-347), and a C-terminal domain (aa 348-433). The <scene name='10/1078094/Active_site/1'>activation loop</scene> of [[STK11]] is located from residues ~202-212. Within the activation loop is F204, which interacts with a hydrophobic pocket on MO25, and is necessary to stabilize the active conformation. Within the αC helix is residue D98 which forms a <scene name='10/1078094/78and98/2'>salt bridge</scene> with K78, further stabilizing the active site and aids in ATP binding. Mg<sup>2+</sup> helps aid ATP binding, however in this structure there is a point mutation (<scene name='10/1078094/D194a/1'>D194A</scene>) to make STK11 incapable of binding Mg<sup>2+</sup>, and thus catalytically inactive. Another loop, the <scene name='10/1078094/B2b3_loop/2'>β2-β3 loop</scene> is essential for binding of STRADα on the N-terminal lobe of STK11. β7-β8 sheets of STK11 also interact with STRADα. In the β2-β3 loop R74 hydrogen bonds with Q251 of STRADα<ref>(1.) Zeqiraj, E., Filippi, B. M., Deak, M., Alessi, D. R., and van Aalten, D. M. (2009) Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation, Science 326, 1707-1711.
</ref>.
</ref>.
=== STRADα ===
=== STRADα ===
Line 21: Line 21:
===Missing Residues===
===Missing Residues===
-
This structure is missing important residues both on STK11 and STRADα. In STRADα, the last portion of the pseudokinase domain is also missing, aside from the WEF motif. This region is important for MO25 binding. From STK11, both the N-terminal domain and C-terminal domain are almost entirely missing. Despite not being essential for catalytic activity, these domains have important kinase-independent function. The N-terminal domain has been shown to negatively regulate [[FAK]], and loss of FAK regulation leads to altered cell motility<ref>(1.) Kline, E. R., Shupe, J., Gilbert-Ross, M., Zhou, W., and Marcus, A. I. (2013) LKB1 represses focal adhesion kinase (FAK) signaling via a FAK-LKB1 complex to regulate FAK site maturation and directional persistence, J Biol Chem 288, 17663-17674.
+
This structure is missing important residues both on STK11 and STRADα. In STRADα, the last portion of the pseudokinase domain is missing, aside from the WEF motif. This region is important for MO25 binding. From STK11, both the N-terminal domain and C-terminal domain are almost entirely missing. Despite not being essential for catalytic activity, these domains have important kinase-independent function. The N-terminal domain has been shown to negatively regulate [[FAK]], and loss of FAK regulation leads to altered cell motility<ref>(1.) Kline, E. R., Shupe, J., Gilbert-Ross, M., Zhou, W., and Marcus, A. I. (2013) LKB1 represses focal adhesion kinase (FAK) signaling via a FAK-LKB1 complex to regulate FAK site maturation and directional persistence, J Biol Chem 288, 17663-17674.
</ref>. The C-terminal domain has been shown to be important for development in ''Drosophila'' through interactions with phosphatidic acid along the plasma membrane, and also contains a farnesylation site to aid in intracellular localization<ref>(1.) Dogliotti, G., Kullmann, L., Dhumale, P., Thiele, C., Panichkina, O., Mendl, G., Houben, R., Haferkamp, S., Puschel, A. W., and Krahn, M. P. (2017) Membrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppression, Nat Commun 8, 15747.
</ref>. The C-terminal domain has been shown to be important for development in ''Drosophila'' through interactions with phosphatidic acid along the plasma membrane, and also contains a farnesylation site to aid in intracellular localization<ref>(1.) Dogliotti, G., Kullmann, L., Dhumale, P., Thiele, C., Panichkina, O., Mendl, G., Houben, R., Haferkamp, S., Puschel, A. W., and Krahn, M. P. (2017) Membrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppression, Nat Commun 8, 15747.
</ref><ref>(1.) Alavizargar, A., Gass, M., Krahn, M. P., and Heuer, A. (2024) Elucidating the Membrane Binding Process of a Disordered Protein: Dynamic Interplay of Anionic Lipids and the Polybasic Region, ACS Phys Chem Au 4, 167-179.
</ref><ref>(1.) Alavizargar, A., Gass, M., Krahn, M. P., and Heuer, A. (2024) Elucidating the Membrane Binding Process of a Disordered Protein: Dynamic Interplay of Anionic Lipids and the Polybasic Region, ACS Phys Chem Au 4, 167-179.

Revision as of 18:26, 30 April 2025

2WTK: Heterotrimeric Complex of STK11, MO25, and STRADα

Heterotrimeric Complex of STK11, MO25, STRADα

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

Peyton Jenkins

Personal tools